D Wang, W Li, R Zhao, L Chen, N Liu, Y Tian, H Zhao… - Cancer research, 2019 - AACR
FDA-approved HDAC inhibitors exhibit dose-limiting adverse effects; thus, we sought to
improve the therapeutic windows for this class of drugs. In this report, we describe a new …